Clinical Trial

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 9, 2023 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Trial Details
NCT Number NCT06125652
Lead Sponsor Xuzhou Medical University
Conditions Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Enrollment 20 participants
Start Date 2023-11-04
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-09